European CHMP recommends license extension of upadacitinib (Rinvoq) for treatment of moderate to severe atopic dermatitis

The license extension is for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

European Medicines Agency